TrialInvestigational new drugs2024

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.

Pranav Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.